- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
NU7441 (KU-57788)
NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
CAS No. 503468-95-9
文献中Selleckの製品使用例（267）
製品安全説明書
現在のバッチを見る：
純度：
99.94%
99.94
NU7441 (KU-57788)と併用されることが多い化合物
NU7441 and KU-0060648 reduce the frequency of the non-homologous end joining (NHEJ) pathway while increasing the rate of homology-directed recombination (HDR).
NU7441 and KU-55933 combination treatment significantly increase X-ray cytotoxicity in MDCK cells.
NU7441 and NU7026 are potent DNA-PK inhibitors that inhibit the DSBs repair pathway and enhance the sensitivity of cancer cells to ionizing radiation or chemo-potentiation.
NU7441 (KU-57788)関連製品
シグナル伝達経路
DNA-PK阻害剤の選択性比較
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | 活性情報 | PMID |
|---|---|---|---|---|---|
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of heat shock response in human INA-6 cells assessed as reduction in HSF-1 mediated upregulation of the HSP72 protein expression at 10 uM preincubated for 4 hrs followed by HSP90 inhibitor and HSR inducer NVP-AUY922 addition measured after 4 hr | 28453931 |
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of heat shock response in human INA-6 cells assessed as reduction in HSF-1 mediated upregulation of the HSP72 mRNA expression at 10 uM preincubated for 4 hrs followed by HSP90 inhibitor and HSR inducer NVP-AUY922 addition measured after 4 hrs b | 28453931 |
| INA-6 | Function assay | 10 uM | 4 hrs | Downregulation of NVP-AUY922-induced HSF-1 protein expression in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by Western blot method | 28453931 |
| INA-6 | Function assay | 10 uM | 4 hrs | Inhibition of NVP-AUY922-induced HSF-1 phosphorylation in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by Western blot method | 28453931 |
| INA-6 | Function assay | 10 uM | 4 hrs | Downregulation of NVP-AUY922-induced HSF-1 mRNA expression in human INA-6 cells at 10 uM preincubated for 4 hrs followed by NVP-AUY922 addition measured after 4 hrs by RT-PCR method | 28453931 |
| NCI-H1755 | Growth Inhibition Assay | IC50=10.2428 μM | SANGER | ||
| EM-2 | Growth Inhibition Assay | IC50=10.2426 μM | SANGER | ||
| DU-4475 | Growth Inhibition Assay | IC50=9.96939 μM | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | IC50=9.70137 μM | SANGER | ||
| HCC1937 | Growth Inhibition Assay | IC50=9.69865 μM | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | IC50=9.1661 μM | SANGER | ||
| A549 | Growth Inhibition Assay | IC50=9.09612 μM | SANGER | ||
| OAW-42 | Growth Inhibition Assay | IC50=8.95964 μM | SANGER | ||
| KNS-62 | Growth Inhibition Assay | IC50=8.37762 μM | SANGER | ||
| HOS | Growth Inhibition Assay | IC50=8.37589 μM | SANGER | ||
| HT | Growth Inhibition Assay | IC50=8.3649 μM | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | IC50=8.34686 μM | SANGER | ||
| SNU-449 | Growth Inhibition Assay | IC50=8.2793 μM | SANGER | ||
| PC-3 | Growth Inhibition Assay | IC50=8.27392 μM | SANGER | ||
| HT-1080 | Growth Inhibition Assay | IC50=8.25093 μM | SANGER | ||
| CHP-134 | Growth Inhibition Assay | IC50=8.24185 μM | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | IC50=8.21122 μM | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | IC50=8.16962 μM | SANGER | ||
| FADU | Growth Inhibition Assay | IC50=8.03654 μM | SANGER | ||
| CAL-12T | Growth Inhibition Assay | IC50=7.94352 μM | SANGER | ||
| NKM-1 | Growth Inhibition Assay | IC50=7.74955 μM | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | IC50=7.74533 μM | SANGER | ||
| ACN | Growth Inhibition Assay | IC50=7.7433 μM | SANGER | ||
| HuO9 | Growth Inhibition Assay | IC50=7.71743 μM | SANGER | ||
| GAMG | Growth Inhibition Assay | IC50=7.64131 μM | SANGER | ||
| AU565 | Growth Inhibition Assay | IC50=7.59833 μM | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | IC50=7.36823 μM | SANGER | ||
| KARPAS-299 | Growth Inhibition Assay | IC50=7.32622 μM | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | IC50=7.31328 μM | SANGER | ||
| SW982 | Growth Inhibition Assay | IC50=7.30203 μM | SANGER | ||
| G-402 | Growth Inhibition Assay | IC50=7.30051 μM | SANGER | ||
| NCI-H82 | Growth Inhibition Assay | IC50=7.26659 μM | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | IC50=7.24359 μM | SANGER | ||
| EPLC-272H | Growth Inhibition Assay | IC50=7.16246 μM | SANGER | ||
| 786-0 | Growth Inhibition Assay | IC50=7.09786 μM | SANGER | ||
| ES8 | Growth Inhibition Assay | IC50=6.97588 μM | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | IC50=6.93213 μM | SANGER | ||
| D-263MG | Growth Inhibition Assay | IC50=6.91068 μM | SANGER | ||
| NBsusSR | Growth Inhibition Assay | IC50=6.82502 μM | SANGER | ||
| NB14 | Growth Inhibition Assay | IC50=6.79761 μM | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | IC50=6.69369 μM | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | IC50=6.64334 μM | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=6.63291 μM | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | IC50=6.32721 μM | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | IC50=6.17522 μM | SANGER | ||
| RVH-421 | Growth Inhibition Assay | IC50=6.07338 μM | SANGER | ||
| MLMA | Growth Inhibition Assay | IC50=5.83606 μM | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | IC50=5.62194 μM | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | IC50=5.56599 μM | SANGER | ||
| A427 | Growth Inhibition Assay | IC50=5.53661 μM | SANGER | ||
| GCIY | Growth Inhibition Assay | IC50=5.51378 μM | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | IC50=5.47636 μM | SANGER | ||
| HSC-2 | Growth Inhibition Assay | IC50=5.41773 μM | SANGER | ||
| NB69 | Growth Inhibition Assay | IC50=5.3242 μM | SANGER | ||
| 23132-87 | Growth Inhibition Assay | IC50=5.32024 μM | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | IC50=5.296 μM | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | IC50=5.25292 μM | SANGER | ||
| HCC70 | Growth Inhibition Assay | IC50=5.03939 μM | SANGER | ||
| MDA-MB-415 | Growth Inhibition Assay | IC50=5.00314 μM | SANGER | ||
| TYK-nu | Growth Inhibition Assay | IC50=4.80128 μM | SANGER | ||
| MEL-HO | Growth Inhibition Assay | IC50=4.77989 μM | SANGER | ||
| L-363 | Growth Inhibition Assay | IC50=4.77116 μM | SANGER | ||
| SN12C | Growth Inhibition Assay | IC50=4.71898 μM | SANGER | ||
| EFO-27 | Growth Inhibition Assay | IC50=4.66525 μM | SANGER | ||
| SF126 | Growth Inhibition Assay | IC50=4.60715 μM | SANGER | ||
| LU-134-A | Growth Inhibition Assay | IC50=4.59685 μM | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | IC50=4.58263 μM | SANGER | ||
| RH-18 | Growth Inhibition Assay | IC50=4.44953 μM | SANGER | ||
| A704 | Growth Inhibition Assay | IC50=4.40888 μM | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | IC50=4.32921 μM | SANGER | ||
| IA-LM | Growth Inhibition Assay | IC50=4.27935 μM | SANGER | ||
| AN3-CA | Growth Inhibition Assay | IC50=4.25813 μM | SANGER | ||
| CAL-51 | Growth Inhibition Assay | IC50=4.24854 μM | SANGER | ||
| EKVX | Growth Inhibition Assay | IC50=4.22524 μM | SANGER | ||
| GOTO | Growth Inhibition Assay | IC50=3.9149 μM | SANGER | ||
| LXF-289 | Growth Inhibition Assay | IC50=3.91041 μM | SANGER | ||
| YH-13 | Growth Inhibition Assay | IC50=3.87189 μM | SANGER | ||
| NOS-1 | Growth Inhibition Assay | IC50=3.65312 μM | SANGER | ||
| MG-63 | Growth Inhibition Assay | IC50=3.62676 μM | SANGER | ||
| 8305C | Growth Inhibition Assay | IC50=3.61736 μM | SANGER | ||
| BHT-101 | Growth Inhibition Assay | IC50=3.59985 μM | SANGER | ||
| U031 | Growth Inhibition Assay | IC50=3.59368 μM | SANGER | ||
| JVM-3 | Growth Inhibition Assay | IC50=3.48077 μM | SANGER | ||
| ES7 | Growth Inhibition Assay | IC50=3.46729 μM | SANGER | ||
| NY | Growth Inhibition Assay | IC50=3.45022 μM | SANGER | ||
| 697 | Growth Inhibition Assay | IC50=3.44993 μM | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | IC50=3.42598 μM | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | IC50=3.41341 μM | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | IC50=3.41278 μM | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | IC50=3.28085 μM | SANGER | ||
| SW962 | Growth Inhibition Assay | IC50=3.20352 μM | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | IC50=3.1531 μM | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | IC50=2.77328 μM | SANGER | ||
| KALS-1 | Growth Inhibition Assay | IC50=2.69633 μM | SANGER | ||
| KG-1 | Growth Inhibition Assay | IC50=2.67924 μM | SANGER | ||
| A101D | Growth Inhibition Assay | IC50=2.61338 μM | SANGER | ||
| HuH-7 | Growth Inhibition Assay | IC50=2.56702 μM | SANGER | ||
| RS4-11 | Growth Inhibition Assay | IC50=2.56023 μM | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | IC50=2.38783 μM | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | IC50=2.3739 μM | SANGER | ||
| DEL | Growth Inhibition Assay | IC50=2.35564 μM | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | IC50=2.21888 μM | SANGER | ||
| G-361 | Growth Inhibition Assay | IC50=2.2168 μM | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=2.19909 μM | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | IC50=2.16687 μM | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=2.16609 μM | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | IC50=2.1649 μM | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | IC50=2.14146 μM | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | IC50=1.79479 μM | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | IC50=1.74013 μM | SANGER | ||
| D-423MG | Growth Inhibition Assay | IC50=1.69361 μM | SANGER | ||
| PA-1 | Growth Inhibition Assay | IC50=1.58294 μM | SANGER | ||
| NEC8 | Growth Inhibition Assay | IC50=1.5535 μM | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | IC50=1.4584 μM | SANGER | ||
| 639-V | Growth Inhibition Assay | IC50=1.44128 μM | SANGER | ||
| HL-60 | Growth Inhibition Assay | IC50=1.3819 μM | SANGER | ||
| NB7 | Growth Inhibition Assay | IC50=1.24745 μM | SANGER | ||
| CHL-1 | Growth Inhibition Assay | IC50=1.21368 μM | SANGER | ||
| HH | Growth Inhibition Assay | IC50=1.18093 μM | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | IC50=1.14231 μM | SANGER | ||
| CTB-1 | Growth Inhibition Assay | IC50=1.11546 μM | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | IC50=0.98833 μM | SANGER | ||
| LoVo | Growth Inhibition Assay | IC50=0.86749 μM | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | IC50=0.62216 μM | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=0.60994 μM | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | IC50=0.46636 μM | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | IC50=0.32345 μM | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | IC50=0.28407 μM | SANGER | ||
| A172 | Growth Inhibition Assay | IC50=0.15316 μM | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | IC50=0.02143 μM | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | IC50=10.5725 μM | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | IC50=10.6164 μM | SANGER | ||
| A2058 | Growth Inhibition Assay | IC50=10.6404 μM | SANGER | ||
| BPH-1 | Growth Inhibition Assay | IC50=10.7145 μM | SANGER | ||
| NB5 | Growth Inhibition Assay | IC50=10.7559 μM | SANGER | ||
| G-401 | Growth Inhibition Assay | IC50=10.7626 μM | SANGER | ||
| CAL-72 | Growth Inhibition Assay | IC50=10.8094 μM | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | IC50=10.8202 μM | SANGER | ||
| C32 | Growth Inhibition Assay | IC50=10.8347 μM | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | IC50=10.8376 μM | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | IC50=10.8586 μM | SANGER | ||
| GMS-10 | Growth Inhibition Assay | IC50=10.8971 μM | SANGER | ||
| K5 | Growth Inhibition Assay | IC50=10.9071 μM | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | IC50=11.0559 μM | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | IC50=11.0714 μM | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | IC50=11.0723 μM | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | IC50=11.1011 μM | SANGER | ||
| CAL-54 | Growth Inhibition Assay | IC50=11.4811 μM | SANGER | ||
| WM-115 | Growth Inhibition Assay | IC50=11.6824 μM | SANGER | ||
| COLO-684 | Growth Inhibition Assay | IC50=11.7267 μM | SANGER | ||
| HOP-62 | Growth Inhibition Assay | IC50=11.7508 μM | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | IC50=11.8961 μM | SANGER | ||
| TE-11 | Growth Inhibition Assay | IC50=11.9315 μM | SANGER | ||
| COLO-679 | Growth Inhibition Assay | IC50=11.946 μM | SANGER | ||
| FTC-133 | Growth Inhibition Assay | IC50=12.0076 μM | SANGER | ||
| D-283MED | Growth Inhibition Assay | IC50=12.0569 μM | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | IC50=12.1902 μM | SANGER | ||
| BALL-1 | Growth Inhibition Assay | IC50=12.2662 μM | SANGER | ||
| GT3TKB | Growth Inhibition Assay | IC50=12.3074 μM | SANGER | ||
| HOP-92 | Growth Inhibition Assay | IC50=12.5233 μM | SANGER | ||
| M14 | Growth Inhibition Assay | IC50=13.0335 μM | SANGER | ||
| SKG-IIIa | Growth Inhibition Assay | IC50=13.0554 μM | SANGER | ||
| Becker | Growth Inhibition Assay | IC50=13.058 μM | SANGER | ||
| ES5 | Growth Inhibition Assay | IC50=13.1356 μM | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | IC50=13.2062 μM | SANGER | ||
| SNU-423 | Growth Inhibition Assay | IC50=13.381 μM | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | IC50=13.6232 μM | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | IC50=13.7475 μM | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | IC50=13.7513 μM | SANGER | ||
| CAL-27 | Growth Inhibition Assay | IC50=14.0727 μM | SANGER | ||
| AGS | Growth Inhibition Assay | IC50=14.1319 μM | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | IC50=14.1488 μM | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | IC50=14.5055 μM | SANGER | ||
| D-566MG | Growth Inhibition Assay | IC50=14.7706 μM | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | IC50=15.1067 μM | SANGER | ||
| TE-5 | Growth Inhibition Assay | IC50=15.2333 μM | SANGER | ||
| 647-V | Growth Inhibition Assay | IC50=15.2705 μM | SANGER | ||
| DMS-114 | Growth Inhibition Assay | IC50=15.3291 μM | SANGER | ||
| ME-180 | Growth Inhibition Assay | IC50=15.4783 μM | SANGER | ||
| MS-1 | Growth Inhibition Assay | IC50=15.5623 μM | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | IC50=15.6245 μM | SANGER | ||
| GB-1 | Growth Inhibition Assay | IC50=15.6437 μM | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | IC50=15.8919 μM | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | IC50=15.8928 μM | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | IC50=15.971 μM | SANGER | ||
| SW1783 | Growth Inhibition Assay | IC50=16.0993 μM | SANGER | ||
| EGI-1 | Growth Inhibition Assay | IC50=16.5365 μM | SANGER | ||
| KGN | Growth Inhibition Assay | IC50=16.5586 μM | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | IC50=16.7662 μM | SANGER | ||
| RH-1 | Growth Inhibition Assay | IC50=16.825 μM | SANGER | ||
| HT-1376 | Growth Inhibition Assay | IC50=16.8446 μM | SANGER | ||
| ZR-75-30 | Growth Inhibition Assay | IC50=16.9361 μM | SANGER | ||
| TI-73 | Growth Inhibition Assay | IC50=16.9408 μM | SANGER | ||
| TK10 | Growth Inhibition Assay | IC50=17.0079 μM | SANGER | ||
| SW684 | Growth Inhibition Assay | IC50=17.0154 μM | SANGER | ||
| RPMI-8866 | Growth Inhibition Assay | IC50=17.0699 μM | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=17.5201 μM | SANGER | ||
| NCI-H2291 | Growth Inhibition Assay | IC50=18.4345 μM | SANGER | ||
| T47D | Growth Inhibition Assay | IC50=18.488 μM | SANGER | ||
| A204 | Growth Inhibition Assay | IC50=18.5452 μM | SANGER | ||
| HT-144 | Growth Inhibition Assay | IC50=18.7427 μM | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | IC50=19.0714 μM | SANGER | ||
| HCC1806 | Growth Inhibition Assay | IC50=19.1591 μM | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | IC50=19.6391 μM | SANGER | ||
| K-562 | Growth Inhibition Assay | IC50=19.8926 μM | SANGER | ||
| D-336MG | Growth Inhibition Assay | IC50=19.9322 μM | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | IC50=20.1559 μM | SANGER | ||
| HEC-1 | Growth Inhibition Assay | IC50=20.4978 μM | SANGER | ||
| EW-13 | Growth Inhibition Assay | IC50=20.5443 μM | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | IC50=20.5583 μM | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | IC50=20.5688 μM | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | IC50=20.6719 μM | SANGER | ||
| LAN-6 | Growth Inhibition Assay | IC50=21.0396 μM | SANGER | ||
| NCI-H1048 | Growth Inhibition Assay | IC50=21.2258 μM | SANGER | ||
| CW-2 | Growth Inhibition Assay | IC50=21.2705 μM | SANGER | ||
| HCC2157 | Growth Inhibition Assay | IC50=21.36 μM | SANGER | ||
| EW-22 | Growth Inhibition Assay | IC50=21.376 μM | SANGER | ||
| A253 | Growth Inhibition Assay | IC50=21.4481 μM | SANGER | ||
| BE-13 | Growth Inhibition Assay | IC50=21.6113 μM | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | IC50=21.6316 μM | SANGER | ||
| ETK-1 | Growth Inhibition Assay | IC50=21.8152 μM | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | IC50=21.8647 μM | SANGER | ||
| HPAF-II | Growth Inhibition Assay | IC50=21.8923 μM | SANGER | ||
| D-542MG | Growth Inhibition Assay | IC50=21.9069 μM | SANGER | ||
| NCI-H630 | Growth Inhibition Assay | IC50=22.0296 μM | SANGER | ||
| TGBC11TKB | Growth Inhibition Assay | IC50=22.049 μM | SANGER | ||
| BCPAP | Growth Inhibition Assay | IC50=22.611 μM | SANGER | ||
| HLE | Growth Inhibition Assay | IC50=22.697 μM | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | IC50=22.735 μM | SANGER | ||
| RD | Growth Inhibition Assay | IC50=22.7518 μM | SANGER | ||
| NCI-H522 | Growth Inhibition Assay | IC50=22.8431 μM | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | IC50=23.0641 μM | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | IC50=23.4683 μM | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | IC50=23.7863 μM | SANGER | ||
| HSC-3 | Growth Inhibition Assay | IC50=23.8527 μM | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | IC50=24.0161 μM | SANGER | ||
| DB | Growth Inhibition Assay | IC50=24.1028 μM | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | IC50=24.3093 μM | SANGER | ||
| MKN1 | Growth Inhibition Assay | IC50=24.68 μM | SANGER | ||
| MN-60 | Growth Inhibition Assay | IC50=24.8519 μM | SANGER | ||
| 8505C | Growth Inhibition Assay | IC50=25.1845 μM | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | IC50=25.2208 μM | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | IC50=25.2483 μM | SANGER | ||
| KM12 | Growth Inhibition Assay | IC50=25.5807 μM | SANGER | ||
| NB13 | Growth Inhibition Assay | IC50=25.5898 μM | SANGER | ||
| HCC2998 | Growth Inhibition Assay | IC50=26.0283 μM | SANGER | ||
| U-118-MG | Growth Inhibition Assay | IC50=26.0808 μM | SANGER | ||
| NB10 | Growth Inhibition Assay | IC50=26.234 μM | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | IC50=27.0704 μM | SANGER | ||
| SW1573 | Growth Inhibition Assay | IC50=27.11 μM | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | IC50=27.1294 μM | SANGER | ||
| DK-MG | Growth Inhibition Assay | IC50=27.1817 μM | SANGER | ||
| RMG-I | Growth Inhibition Assay | IC50=27.2029 μM | SANGER | ||
| SW1088 | Growth Inhibition Assay | IC50=27.5042 μM | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | IC50=27.7593 μM | SANGER | ||
| KP-N-YN | Growth Inhibition Assay | IC50=27.8043 μM | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | IC50=28.2456 μM | SANGER | ||
| CaR-1 | Growth Inhibition Assay | IC50=28.5582 μM | SANGER | ||
| MKN7 | Growth Inhibition Assay | IC50=28.5964 μM | SANGER | ||
| CHP-212 | Growth Inhibition Assay | IC50=28.7401 μM | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | IC50=28.8091 μM | SANGER | ||
| RXF393 | Growth Inhibition Assay | IC50=29.2906 μM | SANGER | ||
| P30-OHK | Growth Inhibition Assay | IC50=29.3048 μM | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | IC50=29.4299 μM | SANGER | ||
| RT-112 | Growth Inhibition Assay | IC50=29.4611 μM | SANGER | ||
| ES1 | Growth Inhibition Assay | IC50=29.8544 μM | SANGER | ||
| HCE-4 | Growth Inhibition Assay | IC50=29.8786 μM | SANGER | ||
| AM-38 | Growth Inhibition Assay | IC50=30.0606 μM | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | IC50=30.8053 μM | SANGER | ||
| TE-9 | Growth Inhibition Assay | IC50=30.8737 μM | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | IC50=30.9638 μM | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | IC50=31.0744 μM | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | IC50=31.0905 μM | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | IC50=31.4651 μM | SANGER | ||
| SCC-4 | Growth Inhibition Assay | IC50=31.9181 μM | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | IC50=32.0128 μM | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=32.0739 μM | SANGER | ||
| Daoy | Growth Inhibition Assay | IC50=32.0838 μM | SANGER | ||
| ES4 | Growth Inhibition Assay | IC50=32.3922 μM | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | IC50=32.4872 μM | SANGER | ||
| C-33-A | Growth Inhibition Assay | IC50=32.7728 μM | SANGER | ||
| BHY | Growth Inhibition Assay | IC50=32.9495 μM | SANGER | ||
| Detroit562 | Growth Inhibition Assay | IC50=33.6657 μM | SANGER | ||
| EW-1 | Growth Inhibition Assay | IC50=33.9322 μM | SANGER | ||
| NCI-H1395 | Growth Inhibition Assay | IC50=34.0799 μM | SANGER | ||
| KM-H2 | Growth Inhibition Assay | IC50=36.4743 μM | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | IC50=36.7541 μM | SANGER | ||
| D-392MG | Growth Inhibition Assay | IC50=37.3344 μM | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | IC50=37.8089 μM | SANGER | ||
| TE-6 | Growth Inhibition Assay | IC50=38.124 μM | SANGER | ||
| HT-3 | Growth Inhibition Assay | IC50=38.4436 μM | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | IC50=38.9519 μM | SANGER | ||
| U251 | Growth Inhibition Assay | IC50=39.0124 μM | SANGER | ||
| GCT | Growth Inhibition Assay | IC50=39.1852 μM | SANGER | ||
| A431 | Growth Inhibition Assay | IC50=39.1894 μM | SANGER | ||
| TE-12 | Growth Inhibition Assay | IC50=39.2448 μM | SANGER | ||
| HMV-II | Growth Inhibition Assay | IC50=39.5047 μM | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | IC50=40.1502 μM | SANGER | ||
| SW13 | Growth Inhibition Assay | IC50=40.519 μM | SANGER | ||
| SF295 | Growth Inhibition Assay | IC50=40.8066 μM | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | IC50=40.9462 μM | SANGER | ||
| TE-1 | Growth Inhibition Assay | IC50=41.8714 μM | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | IC50=42.5289 μM | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | IC50=43.1754 μM | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | IC50=44.0304 μM | SANGER | ||
| SW900 | Growth Inhibition Assay | IC50=44.0758 μM | SANGER | ||
| CAS-1 | Growth Inhibition Assay | IC50=44.0991 μM | SANGER | ||
| TE-8 | Growth Inhibition Assay | IC50=44.5658 μM | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | IC50=44.6112 μM | SANGER | ||
| YKG-1 | Growth Inhibition Assay | IC50=44.781 μM | SANGER | ||
| SNU-C2B | Growth Inhibition Assay | IC50=44.7903 μM | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | IC50=44.8703 μM | SANGER | ||
| U-87-MG | Growth Inhibition Assay | IC50=45.1022 μM | SANGER | ||
| HAL-01 | Growth Inhibition Assay | IC50=45.1379 μM | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | IC50=45.3564 μM | SANGER | ||
| KYSE-150 | Growth Inhibition Assay | IC50=47.1052 μM | SANGER | ||
| OE33 | Growth Inhibition Assay | IC50=47.1429 μM | SANGER | ||
| CAL-62 | Growth Inhibition Assay | IC50=47.4068 μM | SANGER | ||
| TCCSUP | Growth Inhibition Assay | IC50=47.6264 μM | SANGER | ||
| H4 | Growth Inhibition Assay | IC50=47.6621 μM | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | IC50=48.0704 μM | SANGER | ||
| SNB75 | Growth Inhibition Assay | IC50=48.1874 μM | SANGER | ||
| Mo-T | Growth Inhibition Assay | IC50=48.279 μM | SANGER | ||
| BT-549 | Growth Inhibition Assay | IC50=48.3729 μM | SANGER | ||
| IGR-1 | Growth Inhibition Assay | IC50=48.6645 μM | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | IC50=48.7248 μM | SANGER | ||
| ALL-PO | Growth Inhibition Assay | IC50=49.9268 μM | SANGER | ||
| CLL | Function assay | Inhibition of DNA-PK autophosphorylation at Ser2056 residue in human CLL cells by Western blot method, IC50 = 0.03 μM. | 22835870 | ||
| HeLa | Function assay | Inhibition of DNA-PK autophosphorylation at S2056 in human HeLa cells, EC50 = 0.212 μM. | 23855836 | ||
| CHO | Function assay | Inhibition of human ERG expressed in cisapride treated CHO cells by Ion Works assay, IC50 = 14 μM. | 23855836 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| 他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい | |||||
生物活性
| 製品説明 | NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
| In Vitro | ||||
| In vitro |
NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of -induced γH2AX foci and correspondingly decreased -induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits -induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage[7]. |
|||
|---|---|---|---|---|
| 細胞実験 | 細胞株 | SW620, LoVo, V3-YAC and V3 cells | ||
| 濃度 | 0.5 μM or 1 μM | |||
| 反応時間 | 17 hours | |||
| 実験の流れ | The effect of NU7441 on cellular survival following exposure to doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441. |
|||
| 実験結果図 | Methods | Biomarkers | 結果図 | PMID |
| Western blot | p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51 p-mTOR(Ser2448) / mTOR / p-S6K(Thr389) |
|
29344644 | |
| In Vivo | ||
| In Vivo |
NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2] |
|
|---|---|---|
| 動物実験 | 動物モデル | Female rude mice bearing SW620 xenografts |
| 投与量 | 10 mg/kg | |
| 投与経路 | Intraperitoneally administrated | |
化学情報
| 分子量 | 413.49 | 化学式 | C25H19NO3S |
| CAS No. | 503468-95-9 | SDF | Download NU7441 (KU-57788) SDFをダウンロードする |
| Smiles | C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56 | ||
| 保管 | |||
|
In vitro |
DMSO : 5 mg/mL ( (12.09 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。) Water : Insoluble Ethanol : Insoluble |
モル濃度計算器 |
|
in vivo Add solvents to the product individually and in order. |
投与溶液組成計算機 | ||||
実験計算
投与溶液組成計算機(クリア溶液)
ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
mg/kg
g
μL
匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
投与溶媒濃度： mg/ml;
DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )
投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。
投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。
注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
よくある質問（FAQ）
質問1:
Could you please suggest formulations of the drug for in vivo injection?
回答
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
質問2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
回答
Slight color variation due to different processing is normal and usually doesn't interfere with the function.
Tags: NU7441 (KU-57788)を買う | NU7441 (KU-57788) ic50 | NU7441 (KU-57788)供給者 | NU7441 (KU-57788)を購入する | NU7441 (KU-57788)費用 | NU7441 (KU-57788)生産者 | オーダーNU7441 (KU-57788) | NU7441 (KU-57788)化学構造 | NU7441 (KU-57788)分子量 | NU7441 (KU-57788)代理店
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間